HCW Biologics targets IND filing for solid-tumor T-cell engager HCW11-018b in 1H 2027

PUBT · 1d ago
HCW Biologics targets IND filing for solid-tumor T-cell engager HCW11-018b in 1H 2027
  • HCW Biologics kept its IND filing timeline for HCW11-018b on track for 1H 2027, targeting a first-in-human solid-tumor study.
  • A recent FDA Type B meeting provided guidance on remaining steps to support the IND package.
  • Clinical-grade cGMP manufacturing is underway for trial supply.
  • HCW11-018b combines a tissue factor-targeting, CD3-engaging BiTE design with IL-15 signaling and a TGF-β trap to counter tumor immunosuppression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090900PRIMZONEFULLFEED9842642) on October 09, 2026, and is solely responsible for the information contained therein.